Giant prolactinomas: The therapeutic approach

Clinical Endocrinology

Volumn 79, Issue 4, 2013, Pages 447-456

  Moraes, Aline B ^a,b   Marques Dos Santos Silva, Cintia ^a   Vieira Neto, Leonardo ^a,c   Gadelha, Mônica R ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b Instituto Estadual de Diabetes e Endocrinologia Luiz Capriglione   (Brazil)

^c Lagoa Federal Hospital   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

BROMOCRIPTINE; CABERGOLINE; QUINAGOLIDE; TEMOZOLOMIDE;

BLURRED VISION; CELL PROLIFERATION; CYTOREDUCTIVE SURGERY; DIPLOPIA; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERABILITY; DYSKINESIA; EPIDEMIOLOGY; FLUSHING; GAMBLING; HEADACHE; HUMAN; HYPOGONADISM; INTRACRANIAL HYPERTENSION; LEG CRAMP; LIQUORRHEA; MAXIMUM TOLERATED DOSE; NIGHTMARE; NONFUNCTIONING PITUITARY ADENOMA; NOSE OBSTRUCTION; NUCLEAR MAGNETIC RESONANCE IMAGING; ORTHOSTATIC HYPOTENSION; PARESTHESIA; PATIENT MONITORING; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PROLACTINOMA; RADIOTHERAPY; REVIEW; SIDE EFFECT; SURGERY; TUMOR VOLUME; VISUAL FIELD DEFECT;

COMBINED MODALITY THERAPY; DOPAMINE AGONISTS; ERGOLINES; HUMANS; PITUITARY GLAND; PITUITARY NEOPLASMS; PROLACTIN; PROLACTINOMA; TREATMENT OUTCOME; TUMOR BURDEN;

EID: 84883522492     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/cen.12242     Document Type: Review

References (86)

1. Ciccarelli, A., Daly, A.F., &, Beckers, A., (2005) The epidemiology of prolactinomas. Pituitary, 8, 3-6.
2. Shrivastava, R.K., Arginteanu, M.S., King, W.A., et al,. (2002) Giant prolactinomas: clinical management and long-term follow up. Journal of Neurosurgery, 97, 299-306.
3. Delgrange, E., Trouillas, J., Maiter, D., et al,. (1997) Sex-related difference in the growth of prolactinomas: a clinical and proliferation marker study. Journal of Clinical Endocrinology and Metabolism, 82, 2102-2107.
4. Corsello, S.M., Ubertini, G., Altomare, M., et al,. (2003) Giant prolactinomas in men: efficacy of cabergoline treatment. Clinical Endocrinology, 58, 662-670.
5. Shimon, I., Benbassat, C., &, Hadani, M., (2007) Effectiveness of long-term cabergoline treatment for giant prolactinoma: study of 12 men. European Journal of Endocrinology, 156, 225-231.
6. Murphy, F.Y., Vesely, D.L., Jordan, R.M., et al,. (1987) Giant invasive prolactinomas. American Journal of Medicine, 83, 995-1002.
7. Yu, C., Wu, Z., &, Gong, J., (2005) Combined treatment of invasive giant prolactinomas. Pituitary, 8, 61-65.
8. Wu, Z.B., Yu, C.J., Su, Z.P., et al,. (2006) Bromocriptine treatment of invasive giant prolactinomas involving the cavernous sinus: results of a long-term follow up. Journal of Neurosurgery, 104, 54-61.
9. Cho, E.H., Lee, S.A., Chung, J.Y., et al,. (2009) Efficacy and safety of cabergoline as first line treatment for invasive giant prolactinoma. Journal of Korean Medical Science, 24, 874-878.
10. Mallea-Gil, M.S., Cristina, C., Perez-Millan, M.I., et al,. (2009) Invasive giant prolactinoma with loss of therapeutic response to cabergoline: expression of angiogenic markers. Endocrine Pathology, 20, 35-40.
11. Asano, S., Ueki, K., Suzuki, I., et al,. (2001) Clinical features and medical treatment of male prolactinomas. Acta Neurochir (Wien), 143, 465-470.
12. Melmed, S., Casanueva, F.F., Hoffman, A.R., et al,. (2011) Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. Journal of Clinical Endocrinology and Metabolism, 96, 273-288.
13. St-Jean, E., Blain, F., &, Comtois, R., (1996) High prolactin levels may be missed by immunoradiometric assay in patients with macroprolactinomas. Clinical Endocrinology, 44, 305-309.
14. Schofl, C., Schofl-Siegert, B., Karstens, J.H., et al,. (2002) Falsely low serum prolactin in two cases of invasive macroprolactinoma. Pituitary, 5, 261-265.
15. Molitch, M.E., Thorner, M.O., &, Wilson, C., (1997) Management of prolactinomas. Journal of Clinical Endocrinology and Metabolism, 82, 996-1000.
16. Colao, A., Sarno, A.D., Cappabianca, P., et al,. (2003) Gender differences in the prevalence, clinical features and response to cabergoline in hyperprolactinemia. European Journal of Endocrinology, 148, 325-331.
17. Schaller, B., (2005) Gender-related differences in prolactinomas. A clinicopathological study. Neuro Endocrinology Letters, 26, 152-159.
18. Levy, R.A., &, Quint, D.J., (1998) Giant pituitary adenoma with unusual orbital and skull base extension. AJR. American Journal of Roentgenology, 170, 194-196.
19. Chaurasia, P.K., Singh, D., Meher, S., et al,. (2011) Epistaxis as first clinical presentation in a child with giant prolactinoma: case report and review of literature. Journal of Pediatric Neurosciences, 6, 134-137.
20. Alkatari, S., &, Aljohani, N., (2012) Obstructive hydrocephalus, fifth nerve and hypothalamus involvement: acute presentation of a giant prolactinoma. Clinical Medicine Insights. Case Reports, 5, 115-118.
21. Siddiqui, A., Chew, N., &, Miszkiel, K., (2008) Case report: unusual orbital invasion by a giant prolactinoma. British Journal of Radiology, 81, e259-e262.
22. Gurlek, A., Karavitaki, N., Ansorge, O., et al,. (2007) What are the markers of aggressiveness in prolactinomas? Changes in cell biology, extracellular matrix components, angiogenesis and genetics. European Journal of Endocrinology, 156, 143-153.
23. Scheithauer, B.W., Gaffey, T.A., Lloyd, R.V., et al,. (2006) Pathobiology of pituitary adenomas and carcinomas. Neurosurgery, 59, 341-353; discussion 341-353.
24. Meij, B.P., Lopes, M.B., Ellegala, D.B., et al,. (2002) The long-term significance of microscopic dural invasion in 354 patients with pituitary adenomas treated with transsphenoidal surgery. Journal of Neurosurgery, 96, 195-208.
25. Kaltsas, G.A., Nomikos, P., Kontogeorgos, G., et al,. (2005) Clinical review: diagnosis and management of pituitary carcinomas. Journal of Clinical Endocrinology and Metabolism, 90, 3089-3099.
26. Bates, A.S., Farrell, W.E., Bicknell, E.J., et al,. (1997) Allelic deletion in pituitary adenomas reflects aggressive biological activity and has potential value as a prognostic marker. Journal of Clinical Endocrinology and Metabolism, 82, 818-824.
27. Edal, A.L., Skjodt, K., &, Nepper-Rasmussen, H.J., (1997) SIPAP-a new MR classification for pituitary adenomas. Suprasellar, infrasellar, parasellar, anterior and posterior. Acta Radiologica, 38, 30-36.
28. Knosp, E., Steiner, E., Kitz, K., et al,. (1993) Pituitary adenomas with invasion of the cavernous sinus space: a magnetic resonance imaging classification compared with surgical findings. Neurosurgery, 33, 610-617; discussion 617-618.
29. Lloyd, R.V., Kovacs, K., Young, W.F. Jr, et al,. (2004) Pituitary tumours: introduction. In:, R.A. DeLellis, R.V. Lloyd, P.U. Heitz, &, C. Eng, eds. World Health Organization Classification of Tumours Pathology and Genetics of Tumors of Endocrine Organs. IARC Press, Lyon, 10-13.
30. Zemmoura, I., Wierinckx, A., Vasiljevic, A., et al,. (2012) Aggressive and malignant prolactin pituitary tumors: pathological diagnosis and patient management. Pituitary, doi: 10.1007/s11102-012-0448-y
31. Raverot, G., Wierinckx, A., Dantony, E., et al,. (2010) Prognostic factors in prolactin pituitary tumors: clinical, histological, and molecular data from a series of 94 patients with a long postoperative follow-up. Journal of Clinical Endocrinology and Metabolism, 95, 1708-1716.
32. Thapar, K., Kovacs, K., Scheithauer, B.W., et al,. (1996) Proliferative activity and invasiveness among pituitary adenomas and carcinomas: an analysis using the MIB-1 antibody. Neurosurgery, 38, 99-106; discussion 106-107.
33. Whitelaw, B.C., Dworakowska, D., Thomas, N.W., et al,. (2012) Temozolomide in the management of dopamine agonist-resistant prolactinomas. Clinical Endocrinology, 76, 877-886.
34. Gillam, M.P., Molitch, M.E., Lombardi, G., et al,. (2006) Advances in the treatment of prolactinomas. Endocrine Reviews, 27, 485-534.
35. Dash, S., Annamalai, A.K., Simpson, H.L., et al,. (2013) Acute shrinkage of a giant prolactinoma, masquerading as an erosive skull base tumour, with cabergoline. QJM, 106, 85.
36. Acharya, S.V., Gopal, R.A., Menon, P.S., et al,. (2010) Giant prolactinoma and effectiveness of medical management. Endocrine Practice, 16, 42-46.
37. Mascarell, S., &, Sarne, D.H., (2007) Clinical presentation and response to therapy in patients with massive prolactin hypersecretion. Pituitary, 10, 95-101.
38. Minniti, G., Jaffrain-Rea, M.L., Santoro, A., et al,. (2002) Giant prolactinomas presenting as skull base tumors. Surgical Neurology, 57, 99-103; discussion 103-104.
39. Cannavo, S., Curto, L., Squadrito, S., et al,. (1999) Cabergoline: a first-choice treatment in patients with previously untreated prolactin-secreting pituitary adenoma. Journal of Endocrinological Investigation, 22, 354-359.
40. Colao, A., Di Sarno, A., Guerra, E., et al,. (2007) Predictors of remission of hyperprolactinaemia after long-term withdrawal of cabergoline therapy. Clinical Endocrinology, 67, 426-433.
41. Saeki, N., Nakamura, M., Sunami, K., et al,. (1998) Surgical indication after bromocriptine therapy on giant prolactinomas: effects and limitations of the medical treatment. Endocrine Journal, 45, 529-537.
42. Davis, J.R., Sheppard, M.C., &, Heath, D.A., (1990) Giant invasive prolactinoma: a case report and review of nine further cases. The Quarterly Journal of Medicine, 74, 227-238.
43. Sieck, J.O., Niles, N.L., Jinkins, J.R., et al,. (1986) Extrasellar prolactinomas: successful management of 24 patients using bromocriptine. Hormone Research, 23, 167-176.
44. Orrego, J.J., Chandler, W.F., &, Barkan, A.L., (2000) Rapid re-expansion of a macroprolactinoma after early discontinuation of bromocriptine. Pituitary, 3, 189-192.
45. Schultz, P.N., Ginsberg, L., McCutcheon, I.E., et al,. (2000) Quinagolide in the management of prolactinoma. Pituitary, 3, 239-249.
46. Colao, A., Ferone, D., Lastoria, S., et al,. (2000) Hormone levels and tumour size response to quinagolide and cabergoline in patients with prolactin-secreting and clinically non-functioning pituitary adenomas: predictive value of pituitary scintigraphy with 123I-methoxybenzamide. Clinical Endocrinology, 52, 437-445.
47. Webster, J., (1996) A comparative review of the tolerability profiles of dopamine agonists in the treatment of hyperprolactinaemia and inhibition of lactation. Drug Safety, 14, 228-238.
48. Martinkova, J., Trejbalova, L., Sasikova, M., et al,. (2011) Impulse control disorders associated with dopaminergic medication in patients with pituitary adenomas. Clinical Neuropharmacology, 34, 179-181.
49. Valassi, E., Klibanski, A., &, Biller, B.M., (2010) Clinical Review#: potential cardiac valve effects of dopamine agonists in hyperprolactinemia. Journal of Clinical Endocrinology and Metabolism, 95, 1025-1033.
50. Delgado, V., Biermasz, N.R., van Thiel, S.W., et al,. (2012) Changes in heart valve structure and function in patients treated with dopamine agonists for prolactinomas, a 2-year follow-up study. Clinical Endocrinology, 77, 99-105.
51. Dhanwal, D.K., &, Sharma, A.K., (2011) Brain and optic chiasmal herniations into sella after cabergoline therapy of giant prolactinoma. Pituitary, 14, 384-387.
52. Machicado, J.D., Varghese, J.M., &, Orlander, P.R., (2012) Cabergoline-induced pneumocephalus in a medically treated macroprolactinoma. Journal of Clinical Endocrinology and Metabolism, 97, 3412-3413.
53. Balarini Lima, G.A., Machado Ede, O., Dos Santos Silva, C.M., et al,. (2008) Pituitary apoplexy during treatment of cystic macroprolactinomas with cabergoline. Pituitary, 11, 287-292.
54. Moller-Goede, D.L., Brandle, M., Landau, K., et al,. (2011) Pituitary apoplexy: re-evaluation of risk factors for bleeding into pituitary adenomas and impact on outcome. European Journal of Endocrinology, 164, 37-43.
55. Kars, M., Roelfsema, F., Romijn, J.A., et al,. (2006) Malignant prolactinoma: case report and review of the literature. European Journal of Endocrinology, 155, 523-534.
56. Caccavelli, L., Feron, F., Morange, I., et al,. (1994) Decreased expression of the two D2 dopamine receptor isoforms in bromocriptine-resistant prolactinomas. Neuroendocrinology, 60, 314-322.
57. Shimazu, S., Shimatsu, A., Yamada, S., et al,. (2012) Resistance to dopamine agonists in prolactinoma is correlated with reduction of dopamine D2 receptor long isoform mRNA levels. European Journal of Endocrinology, 166, 383-390.
58. Dal Toso, R., Sommer, B., Ewert, M., et al,. (1989) The dopamine D2 receptor: two molecular forms generated by alternative splicing. EMBO Journal, 8, 4025-4034.
59. Peverelli, E., Mantovani, G., Vitali, E., et al,. (2012) Filamin-A is essential for dopamine d2 receptor expression and signaling in tumorous lactotrophs. Journal of Clinical Endocrinology and Metabolism, 97, 967-977.
60. Vroonen, L., Jaffrain-Rea, M.L., Petrossians, P., et al,. (2012) Prolactinomas resistant to standard doses of cabergoline: a multicenter study of 92 patients. European Journal of Endocrinology, 167, 651-662.
61. Verhelst, J., Abs, R., Maiter, D., et al,. (1999) Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients. Journal of Clinical Endocrinology and Metabolism, 84, 2518-2522.
62. Primeau, V., Raftopoulos, C., &, Maiter, D., (2012) Outcomes of transsphenoidal surgery in prolactinomas: improvement of hormonal control in dopamine agonist-resistant patients. European Journal of Endocrinology, 166, 779-786.
63. Komotar, R.J., Starke, R.M., Raper, D.M., et al,. (2012) Endoscopic endonasal compared with microscopic transsphenoidal and open transcranial resection of giant pituitary adenomas. Pituitary, 15, 150-159.
64. Raverot, G., Castinetti, F., Jouanneau, E., et al,. (2012) Pituitary carcinomas and aggressive pituitary tumours: merits and pitfalls of temozolomide treatment. Clinical Endocrinology, 76, 769-775.
65. Hagen, C., Schroeder, H.D., Hansen, S., et al,. (2009) Temozolomide treatment of a pituitary carcinoma and two pituitary macroadenomas resistant to conventional therapy. European Journal of Endocrinology, 161, 631-637.
66. Grebe, S.K., Delahunt, J.W., &, Feek, C.M., (1992) Treatment of extensively invasive (giant) prolactinomas with bromocriptine. New Zealand Medical Journal, 105, 129-131.
67. Kim, W., Clelland, C., Yang, I., et al,. (2012) Comprehensive review of stereotactic radiosurgery for medically and surgically refractory pituitary adenomas. Surgical Neurology International, 3, S79-S89.
68. Loeffler, J.S., &, Shih, H.A., (2011) Radiation therapy in the management of pituitary adenomas. Journal of Clinical Endocrinology and Metabolism, 96, 1992-2003.
69. Sheplan Olsen, L.J., Robles Irizarry, L., Chao, S.T., et al,. (2012) Radiotherapy for prolactin-secreting pituitary tumors. Pituitary, 15, 135-145.
70. Erridge, S.C., Conkey, D.S., Stockton, D., et al,. (2009) Radiotherapy for pituitary adenomas: long-term efficacy and toxicity. Radiotherapy and Oncology, 93, 597-601.
71. Ascoli, P., &, Cavagnini, F., (2006) Hypopituitarism. Pituitary, 9, 335-342.
72. Sonigo, C., Bouilly, J., Carre, N., et al,. (2012) Hyperprolactinemia- induced ovarian acyclicity is reversed by kisspeptin administration. Journal of Clinical Investigation, 122, 3791-3795.
73. Bhasin, S., Cunningham, G.R., Hayes, F.J., et al,. (2010) Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. Journal of Clinical Endocrinology and Metabolism, 95, 2536-2559.
74. Colao, A., Vitale, G., Cappabianca, P., et al,. (2004) Outcome of cabergoline treatment in men with prolactinoma: effects of a 24-month treatment on prolactin levels, tumor mass, recovery of pituitary function, and semen analysis. Journal of Clinical Endocrinology and Metabolism, 89, 1704-1711.
75. Prior, J.C., Cox, T.A., Fairholm, D., et al,. (1987) Testosterone-related exacerbation of a prolactin-producing macroadenoma: possible role for estrogen. Journal of Clinical Endocrinology and Metabolism, 64, 391-394.
76. Gillam, M.P., Middler, S., Freed, D.J., et al,. (2002) The novel use of very high doses of cabergoline and a combination of testosterone and an aromatase inhibitor in the treatment of a giant prolactinoma. Journal of Clinical Endocrinology and Metabolism, 87, 4447-4451.
77. Amir, E., Seruga, B., Niraula, S., et al,. (2011) Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis. Journal of the National Cancer Institute, 103, 1299-1309.
78. Freeman, M.E., Kanyicska, B., Lerant, A., et al,. (2000) Prolactin: structure, function, and regulation of secretion. Physiological Reviews, 80, 1523-1631.
79. Guivarc'h, D., Vincent, J.D., &, Vernier, P., (1998) Alternative splicing of the D2 dopamine receptor messenger ribonucleic acid is modulated by activated sex steroid receptors in the MMQ prolactin cell line. Endocrinology, 139, 4213-4221.
80. Goffin, V., Bernichtein, S., Touraine, P., et al,. (2005) Development and potential clinical uses of human prolactin receptor antagonists. Endocrine Reviews, 26, 400-422.
81. Jaquet, P., Ouafik, L., Saveanu, A., et al,. (1999) Quantitative and functional expression of somatostatin receptor subtypes in human prolactinomas. Journal of Clinical Endocrinology and Metabolism, 84, 3268-3276.
82. Fusco, A., Gunz, G., Jaquet, P., et al,. (2008) Somatostatinergic ligands in dopamine-sensitive and -resistant prolactinomas. European Journal of Endocrinology, 158, 595-603.
83. Hofland, L.J., van der Hoek, J., van Koetsveld, P.M., et al,. (2004) The novel somatostatin analog SOM230 is a potent inhibitor of hormone release by growth hormone- and prolactin-secreting pituitary adenomas in vitro. Journal of Clinical Endocrinology and Metabolism, 89, 1577-1585.
84. Fukuoka, H., Cooper, O., Mizutani, J., et al,. (2011) HER2/ErbB2 receptor signaling in rat and human prolactinoma cells: strategy for targeted prolactinoma therapy. Molecular Endocrinology, 25, 92-103.
85. Al-Azzawi, H., Yacqub-Usman, K., Richardson, A., et al,. (2011) Reversal of endogenous dopamine receptor silencing in pituitary cells augments receptor-mediated apoptosis. Endocrinology, 152, 364-373.
86. Ribeiro, R.S., &, Abucham, J., (2009) Recovery of persistent hypogonadism by clomiphene in males with prolactinomas under dopamine agonist treatment. European Journal of Endocrinology, 161, 163-169.